REBIRTH Mitglieder

Schlegelberger, Brigitte

Schlegelberger, Brigitte, Prof. Dr. med.

Institute of Cell and Molecular Pathology

Hannover Medical School
Carl-Neuberg-Strasse 1
30625 Hannover


Biography / About

Date of Birth:September, 1956
Function:Full (C4) Professor and Head of the Institute of Human Genetics, Hannover Medical School (MHH)


1975 - 1982Study of Human Medicine, Ludwig Maximilian University, Munich, Germany and University of Kiel, Germany
1982License to Practice Medicine
1984Medical Doctoral Thesis, University of Kiel
1992Post-doctoral lecturing qualification (Habilitation) as Professor
1997Board Certification in Human Genetics

Academic appointments and Research posts:

1984 - 2001Research assistant/ Lecturer/ Professor, Institute of Human Genetics, University of Kiel
1986Visiting Scientist, Karolinska Institute, Stockholm, Sweden
1987 - 2000Deputy Director of the Department of Human Genetics, University of Kiel
1993Appointed (C3) Professor of Human Genetics, Charité, Berlin, Germany
1994Appointed (C3) Professor and Chair of the Institute of Human Genetics at the RWTH Aachen, Germany
1996Appointed (C3) Professor of Human Genetics, University of Kiel
2000Research sabbatical at the University of Chicago, IL, USA; the British Columbia Cancer Center, Vancouver, CA; and St. Jude's Children's Research Hospital, Memphis, TE, USA
2001 - 2014Professor (C4) and Director of the Institute of Cell and Molecular Pathology, MHH
Since 2014Director of the Department of Human Genetics, MHH

Other professional activities:

Since 2008Member of the Scientific Committee of the German José Carreras Leukemia Foundation and the international José Carreras Foundation
Since 2012Board member at the GERMAN Cancer AID (Deutsche Krebshilfe)
2012 - 2018Member of the Academic Council (Fachkollegium) 205-03 Human Genetics of the Deutsche Forschungsgemeinschaft (German Research Foundation, DFG)
2015 - 2018Member of the DFG Senate Commission for Fundamental Issues in Genetic Research
Since 2015Member of the Scientific Advisory Board of the Deutsche José Carreras Leukämie-Stiftung e. V. and the External Scientific Advisory Board of the Josep Carreras Leukaemia Research Institute (IJC), Barcelona

Awards and Prizes:

2002Cooperation Prize 2002 awarded by the State of Lower Saxony for successful partnerships between science and industry (Kooperationspreis 2002 des Landes Niedersachsens)

Major research interests:

  • Genetic instability of modified and malignant stem cells
  • Leukemogenesis
  • Array Comparative Genomic Hybridization (CGH)
  • Next Generation Sequencing (NGS)
  • Hereditary cancer

Selected Publications:

  1. Sandbothe M, Buurman R, Reich N, Greiwe L, Vajen B, Gürlevik E, Schäffer V, Eilers M, Kühnel F, Vaquero A, Longerich T, Roessler S, Schirmacher P, Manns MP, Illig T, Schlegelberger B, Skawran B. The microRNA-449 family inhibits TGF-β-mediated liver cancer cell migration by targeting SOX4. J Hepatol. 2017. 11. pii: S0168-8278(17)30008-9. DOI: 10.1016/j.jhep.2017.01.004. [Epub ahead of print]
  2. Manukjan G, Ripperger T, Venturini L, Stadler M, Göhring G, Schambach A, Schlegelberger B, Steinemann D. GABP is necessary for stem/progenitor cell maintenance and myeloid differentiation in human hematopoiesis and chronic myeloid leukemia. Stem Cell Res. 2016. 16(3):677-81. DOI: 10.1016/j.scr.2016.04.007. Epub 2016 Apr 12
  3. Ripperger T, Manukjan G, Meyer J, Wolter S, Schambach A, Bohne J, Modlich U, Li Z, Skawran B, Schlegelberger B, Steinemann D. The heteromeric transcription factor GABP activates the ITGAM/CD11b promoter and induces myeloid differentiation. Biochim Biophys Acta. 2015. 1849:1145-54. DOI: 10.1016/j.bbagrm.2015.07.005.
  4. Schlegelberger B, Kreipe H, Lehmann U, Steinemann D, Ripperger T, Göhring G, Thomay K, Rump A, Di Donato N, Suttorp M. A child with Li-Fraumeni syndrome: Modes to inactivate the second allele of TP53 in three different malignancies. Pediatr Blood Cancer. 2015. 62:1481-4. DOI: 10.1002/pbc.25486.
  5. Woll PS, Kjällquist U, Chowdhury O, Doolittle H, Wedge DC, Thongjuea S, Erlandsson R, Ngara M, Anderson K, Deng Q, Mead AJ, Stenson L, Giustacchini A, Duarte S, Giannoulatou E, Taylor S, Karimi M, Scharenberg C, Mortera-Blanco T, Macaulay IC, Clark SA, Dybedal I, Josefsen D, Fenaux P, Hokland P, Holm MS, Cazzola M, Malcovati L, Tauro S, Bowen D, Boultwood J, Pellagatti A, Pimanda JE, Unnikrishnan A, Vyas P, Göhring G, Schlegelberger B, Tobiasson M, Kvalheim G, Constantinescu SN, Nerlov C, Nilsson L, Campbell PJ, Sandberg R, Papaemmanuil E, Hellström-Lindberg E, Linnarsson S, Jacobsen SE. Myelodysplastic syndromes are propagated by rare and distinct human cancer stem cells in vivo. Cancer Cell. 2014. 25:794-808. Erratum in: Cancer Cell. 2014;25:861. DOI: 10.1016/j.ccr.2014.03.036.
  6. Braun CJ, Boztug K, Paruzynski A, Witzel M, Schwarzer A, Rothe M, Modlich U, Beier R, Göhring G, Steinemann D, Fronza R, Ball CR, Haemmerle R, Naundorf S, Kühlcke K, Rose M, Fraser C, Mathias L, Ferrari R, Abboud MR, Al-Herz W, Kondratenko I, Maródi L, Glimm H, Schlegelberger B, Schambach A, Albert MH, Schmidt M, von Kalle C, Klein C. Gene therapy for Wiskott-Aldrich syndrome--long-term efficacy and genotoxicity. Sci Transl Med. 2014. 6:227ra33. DOI: 10.1126/scitranslmed.3007280.
  7. Thomay K, Schienke A, Vajen B, Modlich U, Schambach A, Hofmann W, Schlegelberger B, Göhring G. Chromosomal instability and telomere shortening in long-term culture of hematopoietic stem cells: insights from a cell culture model of RPS14 haploinsufficiency. Cytogenet Genome Res. 2014. 142:14-20. DOI: 10.1159/000356096.
  8. Didié M, Christalla P, Rubart M, Muppala V, Döker S, Unsöld B, El-Armouche A, Rau T, Eschenhagen T, Schwoerer AP, Ehmke H, Schumacher U, Fuchs S, Lange C, Becker A, Tao W, Scherschel JA, Soonpaa MH, Yang T, Lin Q, Zenke M, Han DW, Schöler HR, Rudolph C, Steinemann D, Schlegelberger B, Kattman S, Witty A, Keller G, Field LJ, Zimmermann WH. Parthenogenetic stem cells for tissue-engineered heart repair. J Clin Invest. 2013. 123(3):1285-98. DOI: 10.1172/JCI66854. Epub 2013 Feb 22.
  9. Rathinam C, Sauer M, Ghosh A, Rudolph C, Hegazy A, Schlegelberger B, Welte K, Klein C. Generation and characterization of a novel hematopoietic progenitor cell line with DC differentiation potential. Leukemia. 2012. 26:2302
  10. Lesinski DA, Heinz N, Pilat-Carotta S, Rudolph C, Jacobs R, Schlegelberger B, Klump H, Schiedlmeier B. Serum- and stromal cell-free hypoxic generation of embryonic stem cell-derived hematopoietic cells in vitro, capable of multilineage repopulation of immunocompetent mice. Stem Cells Transl Med. 2012. 1:581-91. DOI: 10.5966/sctm.2012-0020.


B. Schlegelberger (*1956), PhD, is W3 professor for ‘Human Genetics’ and head of the De-partment of Human Genetics at MHH. She is Coordinator of the Subnetwork Familial Leukemia within the European Reference Network PAEDCAN. Her research focuses on the identification of novel candidate genes for hereditary hematological malignancies. She has extensive knowledge in the area of biosafety of genetically modified stem cells. Since hematopoietic stem cells provide an ideal model system she aims to translate the increasing knowledge, not only into diagnostics, but also build the basis for targeted gene therapies of familial leukemia.

[zurück zur Liste]
Diese Webseite verwendet Cookies und die Webanalyse-Software Google Analytics. Klicken Sie hier für weitere Informationen zum Datenschutz.